Annual Congress Vienna 2003

Saturday, 27.09.2003
Sunday, 28.09.2003
Monday, 29.09.2003
Tuesday, 30.09.2003
Wednesday, 01.10.2003

Citations should be made in the following way: Authors. Title. Eur Respir J 2003; 22: Suppl. 45, abstract number.

Material from 2003:

3196 Abstracts
374 Slide presentations

Material from 2003: Show

Lung cancer staging and combined modality treatment

Oral Presentation
Chairs: J-P. Sculier (Brussels, Belgium), J. B. Putnam (Houston, USA)

Download all media

Resectability after two different chemotherapy regimens: results of the first step of a phase II randomised trial in initially resectable stage I – IIIa nonsmall cell lung cancer conducted by the European lung cancer working party P. Lothaire, T. Berghmans, J. J. Lafitte, V. Giner, M. C. Berchier, A. P. Meert, M. Paesmans, P. Mommen, V. Ninane, J. P. Sculier (Brussels, Bruxelles, Belgium; Lille, Hayange, France; Valencia, Spain)
A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional nonsmall cell lung cancer (NSCLC)
Factors predicting complete surgical resection after induction chemotherapy in patients with initially unresectable non-small cell lung cancer (NSCLC) treated in a randomised trial P. Lothaire, J. J. Lafitte, V. Giner, T. Berghmans, P. Wackenier, M. Paesmans, P. Mommen, P. van Houtte, V. Ninane, J. P. Sculier (Brussels, Mons, Belgium; Lille, France; Valencia, Spain)
A Phase II study of induction carboplatin (CBDCA) and docetaxel (DOC) with concurrent radiation in early-stage non-small cell lung cancer (NSCLC) M. Hayashi, N. Katakami, A. Ikeda, B. Umeda, S. Nishiuchi, K. Hirokawa (Kobe, Japan)
Phase II trial on neoadjuvant chemoradiation with paclitaxel/carboplatin in stage III NSCLC G. Friedel, W. Budach, T. Kyriss, J. Zoller, T. Hehr, H. P. Eulenbruch (Gerlingen, Tuebingen, Germany)
The big lung trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the radical radiotherapy setting D. J. Fairlamb, N. H. Gower, R. Milroy, M. D. Peake, R. M. Rudd, S. G. Spiro, R. J. Stephens, D. Waller (United Kingdom)
A new TNM classification is better than ISS at predicting survival in stage III unresectable non-small cell lung cancer (NSCLC). A study by the European lung cancer working party (ELCWP) T. Berghmans, J. J. Lafitte, J. Thiriaux, P. Van Houtte, J. Lecomte, A. Efremidis, V. Giner, M. Paesmans, J. Klastersky, J. P. Sculier (Bruxelles, Charleroi, Belgium; Lille, France; Athens, Greece; Valence, Spain)
Validation of the TNM classification (6th ed. / 2003) in the staging of small-cell lung cancer (SCLC) H. Bülzebruck, D. Peter (Heidelberg, Germany)